# VIPER-102

Source: https://onco.cc/drugs/viper-102/  
OnCo record `viper-102` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

VIPER-102 is an experimental CAR-T cell therapy from Vittoria Biotherapeutics, in preclinical development for solid tumours.

## Summary

VIPER-102 is a CAR-T cell therapy from Vittoria Biotherapeutics. CAR T cells against an undisclosed solid tumour antigen that the company says is over-expressed by malignant cells and compartmentalised in healthy tissue. Its furthest stage is preclinical development, for solid tumours. No clinical trial naming it is registered on ClinicalTrials.gov. IND-enabling studies per pipeline page. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: VIPER-102
- Modality: CAR-T cell therapy
- Mechanism: CAR T cells against an undisclosed solid tumour antigen that the company says is over-expressed by malignant cells and compartmentalised in healthy tissue.

## Sources

- Vittoria Biotherapeutics: vittoriabio.com: https://vittoriabio.com/pipeline/
- Vittoria Biotherapeutics: vittoriabio.com: https://vittoriabio.com/pipeline/

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Vittoria Biotherapeutics](https://onco.cc/companies/vittoria-biotherapeutics/)

---
JSON: https://onco.cc/api/v1/entities/viper-102.json